This American Academy of Ophthalmology initiative highlights recent data on the new more durable intravitreal anti-vascular endothelial growth factor (VEGF) therapies for the treatment of neovascular age-related macular degeneration (nAMD). This CME collection includes discussion among the expert faculty, an interactive infographic, and patient cases contextualizing clinical trial data for real-world use of these therapies in clinical practice. The educational activities will focus on treatment selection, establishing dosing intervals, and monitoring response to treatment. Patient cases will illustrate best practices for initiating these therapies, switching therapies, and using the longer-acting anti-VEGF therapies to reduce treatment burden.